Specifically, patients with AML evolved from MDS are reported to have a high prevalence of mutations in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2, and patients with therapy-related AML are frequently found to have TP53 mutations [4, 7–9]. This evidence concerns the gene SF3B1 and acute myeloid leukemia.